Clin Mol Hepatol.
2023 Jan;29(1):163-164. 10.3350/cmh.2022.0326.
Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
- Affiliations
-
- 1Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China
- KMID: 2538212
- DOI: http://doi.org/10.3350/cmh.2022.0326
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
- Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways
- Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
- Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease
- Pathology of nonalcoholic steatohepatitis
